Lilly (Eli) (LLY) Stock Price, Fundamentals & Analysis

What LLY does

Lilly (Eli) (LLY) discovers, develops, manufactures, and markets human pharmaceutical products across the United States, Europe, China, Japan, and internationally. The company is best known for its diabetes and obesity portfolio, which includes insulin products such as Basaglar and Humalog, as well as GLP-1 receptor agonists like Mounjaro and Zepbound. It also has a broad oncology pipeline with treatments such as Jaypirca for chronic lymphocytic leukemia and Retevmo for metastatic non-small cell lung cancer, alongside immunology medicines like Olumiant and Taltz. Lilly (Eli) is part of the S&P 500 and operates in the same sector as peers such as Vertex Pharmaceuticals (VRTX) and Boston Scientific (BSX).

Key numbers explained

• 1,150.99 USD is the current share price, representing the cost to buy one share of Lilly (Eli) today.
• The trailing P/E ratio of 38.6 compares the share price to the last 12 months of earnings per share (29.84 USD), showing how much investors pay for each dollar of recent profit.
• The forward P/E ratio of 24.2 uses expected future earnings, which can be lower if the market anticipates growth.
• 0.59% is the dividend yield, meaning the annual dividend represents roughly 0.59% of the share price.
• The ex-dividend date is 14 aug. 2026; to receive the dividend, you must own the stock before this date.
• 22% of earnings are paid out as dividends, so the company retains most of its profit for reinvestment.
• 0.5 is the beta, indicating Lilly (Eli) has historically been less volatile than the overall market.
• 57.7% is the price change over the last 52 weeks, measured from one year ago to the current price.

Recent news

Headlines highlight investor attention on Lilly (Eli)'s pipeline and competitive landscape. One story asks whether Retatrutide could become a 10 billion USD revenue opportunity, while another notes a 6.5 billion USD plant investment to support oral GLP-1 production. Other articles compare Lilly (Eli) with peers such as AbbVie, Pfizer, and Novo Nordisk, focusing on how their strategies and pipelines differ.

What to watch

Investors in Lilly (Eli) typically monitor pipeline readouts, regulatory decisions, and pricing dynamics in the pharmaceutical industry. The company's large market capitalisation of 1.03T USD and high price-to-book of 30.29 reflect its growth expectations, while its 162.1% debt-to-equity ratio is a factor in how it finances operations. Revenue growth of 47.7% and strong margins, such as 33.5% profit margin and 54.2% operating margin, are also key indicators of business performance. For broader context, Lilly (Eli) can be compared with other healthcare stocks like Cigna (CI) or Elevance Health (ELV).